A phase 3 trial of QL1706, bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07025239 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 430 participants, started 2025-07 and due to reach its primary completion in 2028-07. Interventions recorded: QL1706; Bevacizumab; Oxaliplatin; Capecitabine; Placebo. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression Free Survival (PFS) Assessed by the Independent Radiology Review Committee (IRRC). Colorectal eligibility wording from the registry: "* Unresectable metastatic colorectal adenocarcinoma confirmed by histopathology examination;". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QL1706, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/